2025-08-15T10:42:03-05:00 2024-09-30 390859910 BAKER TILLY ADVISORY GROUP LP 225 S 6TH ST 2300 MINNEAPOLIS MN 55402 990 2023-10-01 411704734 NMDP FOUNDATION NMDP 7634068700 500 N 5TH ST MINNEAPOLIS MN 554011206 KATHERINE HEYERDAHL CHIEF FINANCIAL OFFICER 7634068700 2025-08-14 1 1 KAREN A GRIES P00078514 6128764500 2025-08-14 2023 2025-03-06 01:10:19Z ERICA JENSEN 500 N 5TH ST MINNEAPOLIS MN 554011206 34289320 0 X WWW.NMDP.ORG X 1991 MN RAISES FUNDS TO SUPPORT THE NATIONAL MARROW DONOR PROGRAM (NMDP) MISSION: WE SAVE LIVES THROUGH CELLULAR THERAPY. 17 16 45 3000 0 0 18893262 22907977 0 0 350756 2335205 -555030 -938540 18688988 24304642 9700536 12389221 0 0 5791779 7240574 612029 482576 2175120 2157082 1952631 18261426 22065002 427562 2239640 15913956 18372366 1878244 1852736 14035712 16519630 X SEE SCHEDULE O 0 0 6639306 6639306 0 PATIENT ASSISTANCE:THE NMDP FOUNDATION PROVIDES FINANCIAL ASSISTANCE TO PATIENTS THROUGHOUT EACH STAGE OF THE TRANSPLANT PROCESS. FUNDED BY PHILANTHROPY, IN FY24, MORE THAN $6.3 MILLION WAS PROVIDED TO OVER 3,300 PATIENTS FROM 160 TRANSPLANT CENTERS. IN FY24, THE PROPORTION OF GRANT RECIPIENTS WHO IDENTIFIED AS NON-HISPANIC WHITE RANGED FROM 0%-66% DEPENDING ON THE GRANT TYPE. FOR THE SICKLE CELL FERTILITY PRESERVATION GRANT, WHICH HELPS PAY FOR FERTILITY PRESERVATION AND STORAGE PRE-TRANSPLANT FOR SICKLE CELL DISEASE, ALL RECIPIENTS IDENTIFIED AS EITHER BLACK OR AFRICAN AMERICAN. FOR THE POST-TRANSPLANT SUPPORT ASSISTANCE (TSA) GRANT, 66% OF RECIPIENTS IDENTIFIED AS NON-HISPANIC WHITE. THE SEARCH ASSISTANCE FUND GRANT (SAF) SUPPORT PATIENTS PRE-TRANSPLANT WHO HAVE BARRIERS RELATED TO INSURANCE THAT DELAY OR PREVENT THEM FROM FINDING A DONOR OR CORD BLOOD UNIT. THIS GRANT HELPS PATIENTS START THE SEARCH FOR AN UNRELATED DONOR OR CORD BLOOD UNIT BY GIVING TRANSPLANT CENTERS A GUARANTEE OF PAYMENT FOR SPECIFIC SEARCH AND/OR PROCUREMENT COSTS SHOULD THEY NOT BE COVERED BY INSURANCE. THERE WERE 6 PATIENTS APPROVED FOR SAF IN FY24.THE SICKLE CELL FERTILITY PRESERVATION GRANT HELPS PAY FOR FERTILITY PRESERVATION AND STORAGE FEES FOR PATIENTS WITH SICKLE CELL DISEASE PREPARING FOR TRANSPLANT. THIS GRANT IS PAID TO THE FERTILITY PRESERVATION CLINIC OR PATIENT WHEN INSURANCE DOES NOT COVER THIS COST. IN FY24, THIS GRANT WAS DISTRIBUTED TO 15 PATIENTS WITH AN AVERAGE AWARD AMOUNT OF $4,680. NMDP ALSO PROVIDES FUNDING TO HELP WITH THE MANY UNCOVERED OUT-OF-POCKET EXPENSES FOR PATIENTS BEFORE AND AFTER TRANSPLANT. THE TSA GRANT PROVIDES DIRECT FINANCIAL ASSISTANCE TO QUALIFIED FAMILIES BOTH PRE- AND POST-TRANSPLANT. TSA HELPS WITH EXPENSES SUCH AS TRANSPORTATION, TEMPORARY RELOCATION, COPAYS AND INSURANCE PREMIUMS. IN FY24, 3,337 TSA AWARDS WERE GRANTED TO 2,649 PATIENTS PRE- AND POST-TRANSPLANT WITH THE AVERAGE AWARD BEING $1,418.THE JOHN AND CARYN CAMIOLO SURVIVORSHIP GRANT (CAM) PROVIDES DIRECT FINANCIAL ASSISTANCE TO ELIGIBLE PATIENTS, WHO ARE AT LEAST THREE MONTHS POST-TRANSPLANT AND WHO ARE ACTIVELY RECEIVING TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE. CAM HELPS WITH UNCOVERED COSTS OF TREATMENT AND PRESCRIPTIONS. IN FY24, 206 PATIENTS WERE HELPED THROUGH THE CAM GRANT WITH EACH PATIENT AWARDED $750.THE CHELL TRAVEL GRANT PROVIDES DIRECT FINANCIAL ASSISTANCE TO ELIGIBLE PATIENTS WHO NEEDED ASSISTANCE WITH TRAVEL COSTS TO PARTICIPATE IN CLINICAL TRIALS THAT TREAT BLOOD CANCERS OR BLOOD DISORDERS. FOR THIS GRANT, 41% OF RECIPIENTS IDENTIFIED AS NON-HISPANIC WHITE. IN FY24, 204 PATIENTS RECEIVED THE CHELL TRAVEL GRANT WITH THE AVERAGE AWARD AMOUNT BEING $1,485.TWO CRISIS GRANTS HELP PATIENTS EXPERIENCING A SIGNIFICANT CRISIS EVENT IMPACTING ACCESS TO TRANSPLANT OR POST-TRANSPLANT CARE. THE IRA AND DIANA RIKLIS CRISIS GRANT PROVIDES UP TO $10,000 IN DIRECT FINANCIAL ASSISTANCE TO QUALIFIED PATIENTS POST-TRANSPLANT AND THE MAKE ME STRONGER CRISIS GRANT PROVIDES UP TO $15,000 PRE-TRANSPLANT. IN FY24, 47 PATIENTS WERE HELPED THROUGH THESE CRISIS GRANTS WITH THE AVERAGE AWARD AMOUNT BEING $8,842. A COMMITTEE OF BMT SOCIAL WORKERS AND NAVIGATORS REVIEWS EACH CRISIS APPLICATION TO ENSURE EQUITABLE DISTRIBUTION OF THIS GRANT. IN FY24, 47% OF GRANT RECIPIENTS IDENTIFIED AS NON-HISPANIC WHITE. 2306006 2305672 0 RECRUITMENT:THE NMDP REGISTRY IS THE MOST DIVERSE LISTING OF POTENTIAL DONORS AND CORD BLOOD UNITS IN THE WORLD. EVERY SEARCH THROUGH NMDP PROVIDES PATIENTS WITH ACCESS TO MORE THAN 44 MILLION POTENTIAL ADULT DONORS AND MORE THAN 820,000 CORD BLOOD UNITS WORLDWIDE. THE BEST MATCH FOR A PATIENT IS TYPICALLY SOMEONE WHO SHARES THEIR ETHNIC BACKGROUND. IMPROVING THE ETHNIC DIVERSITY OF THE NMDP REGISTRY IMPROVES ALL PATIENTS' ODDS OF FINDING THEIR BEST MATCH, REGARDLESS OF ETHNIC BACKGROUND.PEOPLE BETWEEN THE AGES OF 18 AND 30 ARE MOST URGENTLY NEEDED. RESEARCH HAS SHOWN THAT CELLS FROM YOUNGER DONORS LEAD TO BETTER LONG-TERM SURVIVAL FOR PATIENTS.IN FY24, MORE THAN 240,000 POTENTIAL DONORS JOINED THE NMDP REGISTRY AND MORE THAN 4,400 UMBILICAL CORD UNITS WERE ADDED TO THE REGISTRY. 1983699 1983699 0 RESEARCH: RESEARCH INNOVATIONS ARE CRITICAL TO EXPANDING TREATMENT TO MORE PATIENTS AND IMPROVING OUTCOMES. EACH YEAR, THE NMDP FOUNDATION IS PROUD TO INVEST IN RESEARCH THROUGH:THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM: THE AMY PROGRAM FUNDS EARLY CAREER INVESTIGATORS FOCUSED ON ADVANCES IN THE PREVENTION AND TREATMENT OF POST-CELL THERAPY COMPLICATIONS (E.G., GRAFT-VERSUS-HOST -DISEASE AND INFECTION).IN 2024, WE FUNDED THE WORK OF 14 AMY SCHOLARS. AMY SCHOLARS HAVE GONE ON TO BECOME LEADERS IN THE FIELD, PURSUING SCIENTIFIC ADVANCES THAT HELP NMDP PATIENTS LIVE LONGER, HEALTHIER LIVES. SINCE 1998, THE NMDP FOUNDATION HAS INVESTED NEARLY $12.5 MILLION TO HELP LAUNCH THE CAREERS OF 51 YOUNG PHYSICIAN-SCIENTISTS. AFTER RECEIVING THEIR NMDP AMY SCHOLAR AWARD, 51 YOUNG PHYSICIAN-SCIENTISTS HAVE GONE ON TO WIN MORE THAN $250 MILLION IN SUBSEQUENT GOVERNMENT GRANT FUNDING TO PURSUE THE DISCOVERIES TO HELP PATIENTS LIVE LONGER, HEALTHIER LIVES AFTER CELL THERAPY. TODAY, THE AMY STRELZER MANASEVIT RESEARCH PROGRAM FOR THE STUDY OF POST-CELL THERAPY COMPLICATIONS IS ONE OF THE LARGEST AND MOST COVETED FELLOWSHIPS IN THE FIELD OF TRANSPLANTATION.NMDP DONOR FOR ALL: THIS SERIES OF TRANSFORMATIONAL MULTI-CENTER CLINICAL TRIALS ARE TESTING A NEW TRANSPLANT PROTOCOL AIMED AT MAKING MISMATCHED DONOR TRANSPLANTS SAFER AND MORE EFFECTIVE, WITH THE GOAL OF EXPANDING ACCESS TO TRANSPLANT TO THOUSANDS OF PATIENTS WHO LACK A FULLY MATCHED DONOR.ANTHONY NOLAN TRUST: PROVIDE SUPPORT TO THE ANTHONY NOLAN RESEARCH INSTITUTE TO CONTINUE DEVELOPMENT AND MAINTENANCE OF AN HLA CLASS I AND II SEQUENCE DATABASE AND PROVISION OF HLA CLASS I AND II SEQUENCE INFORMATION.CIBMTR (THE CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH) A PARTNERSHIP BETWEEN THE MEDICAL COLLEGE OF WISCONSIN AND NMDP IS THE LEADING HUB FOR TRANSPLANT AND CELL THERAPY RESEARCH. THE NMDP FOUNDATION HELPS TO FUND VARIOUS OTHER INNOVATIVE RESEARCH STUDIES LED AND MANAGED BY THE CIBMTR. 7197956 1460544 0 OTHER PROGRAM:THE NMDP FOUNDATION PARTNERS WITH NMDP TO ADVANCE VARIOUS INITIATIVES. THESE PROGRAMS INCLUDE:NMDP PROVIDES COMPREHENSIVE EDUCATION AND SUPPORT SERVICES TO PATIENTS AND THEIR FAMILIES THROUGH ONE-ON-ONE NAVIGATION SUPPORT, VIDEO, PRINTED, AND DIGITAL EDUCATION RESOURCES, COUNSELING, NMDP PEER CONNECT PROGRAM, NMDP SURVIVORSHIP PROGRAM, NMDP SICKLE CELL WARRIOR PROGRAM, AND THE JASON CARTER CLINICAL TRIALS SEARCH AND SUPPORT PROGRAM, WHICH HELPS PATIENTS WITH LIFE-THREATENING BLOOD DISORDERS FIND CLINICAL TRIALS. THE NMDP FOUNDATION RAISES FUNDS TO SUPPORT THESE CRITICAL SERVICES.NMDP ALLOCATES COMPENSATION AND BENEFITS AND OCCUPANCY COSTS TO PROGRAMS BASED ON EMPLOYEE RESPONSIBILITIES. 7197956 1460544 0 18126967 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 1 1 1 1 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 376 0 1 45 1 0 1 MX 0 0 0 1 1 0 0 0 0 0 0 X 17 16 0 0 1 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X KATHERINE HEYERDAHL 7634064275 500 N 5TH ST MINNEAPOLIS MN 554011206 AMY RONNEBERG NMDP CHIEF EXECUTIVE OFFICER 2.00 48.00 X X 0 1538663 455038 MICHAEL STEWART CHAIR 1.00 0.00 X X 0 0 0 MELISSA KONG VICE CHAIR 1.00 0.00 X X 0 0 0 RAMESH SUBRAHMANIAN SECRETARY 1.00 0.00 X X 0 0 0 DIANNA CERVANTES TREASURER 1.00 0.00 X X 0 0 0 JASON AHLGREN DIRECTOR 1.00 0.00 X 0 0 0 GUSTAVO ALCOCER DIRECTOR 1.00 0.00 X 0 0 0 SARAH ASMA DIRECTOR 1.00 0.00 X 0 0 0 ANDREW BLOCK DIRECTOR 1.00 0.00 X 0 0 0 BILL FURLONG DIRECTOR 1.00 0.00 X 0 0 0 SULEIKA JAOUAD DIRECTOR 1.00 0.00 X 0 0 0 BRUCE MANASEVIT DIRECTOR 1.00 0.00 X 0 0 0 JOHN PRESLEY DIRECTOR 1.00 0.00 X 0 0 0 DERYN POMEROY DIRECTOR 1.00 0.00 X 0 0 0 RAYNE ROUCE DIRECTOR 1.00 0.00 X 0 0 0 MELODY SMITH DIRECTOR 1.00 0.00 X 0 0 0 REBECCA WENNGATZ DIRECTOR 1.00 0.00 X 0 0 0 KRISTA DUSIL CHIEF FINANCIAL OFFICER (THRU 2/24) 1.00 49.00 X 0 649755 53242 KATHERINE HEYERDAHL CHIEF FINANCIAL OFFICER (BEGAN 4/24) 2.00 48.00 X 0 0 0 JOY KING CHIEF ADVANCEMENT OFFICER 20.00 30.00 X 230187 345282 168631 TODD PETERSON VICE PRESIDENT, ADVANCEMENT 50.00 0.00 X 291111 0 84039 ANGIE FITZGERALD VP, CORPORATE & FOUNDATION PARTNERSHIPS 50.00 0.00 X 274522 0 64855 ALEX MENSING SR. DIRECTOR, SUPPORTER EXPERIENCE & ENGAGEMENT 50.00 0.00 X 199924 0 46470 DANIEL LEE DIRECTOR, MAJOR AND PLANNED GIFTS 50.00 0.00 X 190612 0 32174 KEVIN HEALY DIRECTOR, ADVANCEMENT SERVICES 50.00 0.00 X 182633 0 42949 GINA GRAVES FORMER OFFICER 0.00 0.00 X 0 239958 3353 1368989 2773658 950751 16 1 1 0 MMS USA INVESTMENTS INC DBA EPSILON AGEN 35 WEST WACKER DRVIE CHICAGO IL 60601 FUNDRAISING AND MEDIA BUYING SUPPORT 550986 STREAMWORKS 640 PHEASANT RIDGE DRIVE NORTHEAST BLAINE MN 55449 CREATIVE, PRINT AND MAIL SERVICES 538206 BLACKBAUD PO BOX 844827 BOSTON MA 02284 SOFTWARE SUPPORT 167035 25 BROADWAY BALLROOM DBA CIPRIANI 25 BROADWAY 110 EAST 42ND ST NEW YORK NY 10017 FACILITY RENTAL AND EVENT SERVICES 126163 WALK THE MOON MEDIA 5307 MALIBU DRIVE EDINA MN 55436 VIDEOGRAPHY SERVICES 114230 5 1649926 7586216 13671835 255801 22907977 463724 463724 10709627 8838146 1871481 1871481 1871481 162044 1649926 1140588 -978544 -978544 45940 5944 39996 39996 FOREIGN CURRENCY GAIN 900099 8 8 8 24304642 0 0 1396665 6048966 6048966 6333478 6333478 6777 6777 270159 186109 30434 53616 5317449 3443855 950476 923118 321306 221343 36196 63767 971887 595605 223392 152890 359773 247842 40529 71402 25000 25000 482576 482576 18476 18476 456440 351459 9129 95852 325970 117349 19558 189063 362751 265860 90013 6878 184800 184800 395857 272700 44594 78563 29223 29223 RECOGNITION 98956 35624 5937 57395 REGISTRATIONS 55158 55158 22065002 18126967 1762915 2175120 1415756 2008741 3247472 3261229 1561 130150 189625 11119017 12912771 15913956 18372366 1878244 1838532 14204 1878244 1852736 X 4107242 4690433 9928470 11829197 14035712 16519630 15913956 18372366 2239640 244278 0 X 0 1 X 1 0 X 18034650 20737956 13066515 18893262 22907977 93640360 18034650 20737956 13066515 18893262 22907977 93640360 35381692 58258668 238703 260691 293611 283513 463724 1540242 3 -70 -259 8 -318 95180284 0.61210 0.65640 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: FOREIGN CURRENCY GAIN - 2019 AMOUNT: $ 0. 2020 AMOUNT: $ 3. 2021 AMOUNT: $ -70. 2022 AMOUNT: $ -259. 2023 AMOUNT: $ 8. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4820923 -39900 998624 205880 7460 5566307 4542124 19605 444680 180000 5486 4820923 5550447 465 -832236 172000 4552 4542124 5098748 60000 554109 160000 2410 5550447 4612433 200500 285815 5098748 0.63110 0.36890 0.00000 0 0 0 X PART V, LINE 4: THE INTENDED USES OF THE ENDOWMENT FUNDS ARE TO SUPPORT RESEARCH AND PATIENT ASSISTANCE GRANTS. PART X, LINE 2: ORGANIZATION'S LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER ASC 740 THE INTERNAL REVENUE SERVICE HAS DETERMINED THAT THE PROGRAM AND NMDP FOUNDATION ARE TAX-EXEMPT ORGANIZATIONS UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE NOT-FOR-PROFIT STATUS OF THE PROGRAM AND NMDP FOUNDATION ARE CONSIDERED TAX POSITIONS UNDER FASB ASC 740, INCOME TAXES. THE ORGANIZATION FOLLOWS THE ACCOUNTING STANDARDS FOR CONTINGENCIES IN EVALUATING UNCERTAIN TAX POSITIONS. THIS GUIDANCE PRESCRIBES RECOGNITION THRESHOLD PRINCIPLES FOR THE FINANCIAL STATEMENT RECOGNITION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN ON A TAX RETURN THAT ARE NOT CERTAIN TO BE REALIZED. NO LIABILITY HAS BEEN RECOGNIZED BY THE ORGANIZATION FOR UNCERTAIN TAX POSITIONS AS OF SEPTEMBER 30, 2024 OR 2023. THE ORGANIZATION'S TAX RETURNS ARE SUBJECT TO REVIEW AND EXAMINATION BY FEDERAL AND STATE AUTHORITIES. 0 0 0 0 0 0 0 0 0 0 BONE MARROW/ STEM CELL DONOR ASSISTANCE NORTH AMERICA 19 5358 CHECK/WIRE PATIENT GRANT NORTH AMERICA 1 1419 CHECK/WIRE 0 0 1 0 0 0 PART I, LINE 2: GRANTS PROVIDED IN NORTH AMERICA INCLUDE GRANTS TO MEXICO AS PART OF A LONG-STANDING BONE MARROW AND STEM CELL DONOR ASSISTANCE PROGRAM TO REIMBURSE LOSS OF INCOME CAUSED BY THE DONOR TAKING UNPAID LEAVE FROM WORK IN ORDER TO DONATE LIFE-SAVING CELLS. THE GRANTEES ARE REQUIRED TO SUBMIT AN EMPLOYER LETTER OR A PAY STUB TO DEMONSTRATE LOST INCOME. AN NMDP REPRESENTATIVE COMPLETES THE APPLICATION ON BEHALF OF THE DONOR. AN INTERNAL TEAM REVIEWS ALL APPLICATIONS AND SUPPORTING DOCUMENTS. ALL OTHER GRANTS IN NORTH AMERICA ARE PART OF THE NMDP FOUNDATION PATIENT FINANCIAL ASSISTANCE PROGRAM. PATIENTS APPLY FOR PRE- AND POST-TRANSPLANT SUPPORT GRANTS THROUGH AN ONLINE APPLICATION. THESE APPLICATIONS FOR PATIENT ASSISTANCE ARE TRACKED IN A ORACLE CUSTOM-BUILT MODULE AND MONITORED BY THE PATIENT OUTCOMES AND EXPERIENCES TEAM, A DEPARTMENT WITHIN NATIONAL MARROW DONOR PROGRAM (NMDP). NMDP EXPENDITURE POLICES ARE FOLLOWED TO ENSURE APPROVALS AND CONTROLS ARE MAINTAINED TO DISBURSE GRANT FUNDS INTERNATIONALLY. X X X X X X 1 COMMUNITY COUSELING SERVICE 527 MADISON AVENUE 5TH FLOOR NEW YORK NY 10022 FUNDRAISING CONSULTING 0 0 448604 0 MMS USA INVESTMENTS INC DBA EPSILON AGENCY LLC 35 WEST WACKER DRIVE CHICAGO IL 60601 FUNDRAISING CONSULTING 0 0 25097 0 GOODUNITED 769 MEETING STREET CHARLESTON SC 29403 FUNDRAISING CONSULTING 0 0 7200 0 480901 AL AK AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI MINNEAPOLIS GALA 798275 737407 60868 1104 47490 81219 127139 97457 NEW YORK GALA 419854 376415 43439 143425 94905 8984 3 593841 536104 57737 288755 46923 49403 114984 38800 1811970 1649926 162044 289859 237838 130622 337028 145241 1140588 -978544 29400 5649 165 0 16540 130 0 45940 5649 295 5944 39996 MN CA 1 0 1 0 1.00000 TODD PETERSON 500 N 5TH STREET MINNEAPOLIS MN 55401 0 STACEY CHASE GAMING COORDINATOR X 0 SCHEDULE G, PART I, LINE 2B, COLUMN (V) THE GROSS RECEIPTS FROM ACTIVITIES ASSISTED BY PROFESSIONAL FUNDRAISERS CANNOT BE SEPARATELY REPORTED AS THE WORK PERFORMED BY FUNDRAISERS AIDS IN MANY FUNDRAISING INITIATIVES THROUGHOUT THE FISCAL YEAR. PART III, LINE 16: OTHER GAMING MANAGER INCLUDES AMANDA ALBERTSON, WHO OBTAINS LICENSES AND MANAGES THE PLANNING AND EXECUTION OF RAFFLES. 1 NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 2305672 0 DONOR RECRUITMENT NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 1078699 0 RESEARCH NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 834833 0 PATIENT ASSISTANCE NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 464924 0 VARIOUS NMDP PROGRAMS NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 405238 0 PROGRAM SUPPORT-SALARY NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 54600 0 CLINICAL TRIALS SUPPORT DANA FARBER CANCER INSTITUTE PO BOX 414744 BOSTON MA 02241 042263040 501(C)(3) 40000 0 RESEARCH FRED HUTCHINSON CANCER RESEARCH CENTER MAILSTOP LF-272 PO BOX 19024 SEATTLE WA 98109 237156071 501(C)(3) 240000 0 RESEARCH INDIANA UNIVERSITY 1024 EAST 3RD ST ROOM 132 BLOOMINGTON IN 47405 356001673 501(C)(3) 80000 0 RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 80000 0 RESEARCH MEMORIAL SLOAN KETTERING CANCER RESEARCH CENTER 633 3RD AVENUE 4TH FLOOR NEW YORK NY 10017 131924236 501(C)(3) 80000 0 RESEARCH REGENTS OF THE UNIVERSITY OF COLORADO MAILSTOP F-754 1665 AURORA COURT AURORA CO 80045 846000555 501(C)(3) 25000 0 RESEARCH STANFORD UNIVERSITY DEPT 33725 PO BOX 39000 SAN FRANCISCO CA 94139 941156365 501(C)(3) 120000 0 RESEARCH UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL PO BOX 402420 ATLANTA GA 30384 566001393 501(C)(3) 80000 0 RESEARCH UNIVERSITY OF PITTSBURGH PO BOX 371220 PITTSBURGH PA 15251 250965591 501(C)(3) 40000 0 RESEARCH UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD HOUSTON TX 77030 746001118 501(C)(3) 80000 0 RESEARCH WASHINGTON UNIVERSITY OF ST LOUIS 600 SOUTH EUCLID AVENUE ST LOUIS MO 63110 430654872 501(C)(3) 40000 0 RESEARCH 12 0 PATIENT TRANSPLANT ASSISTANCE 2706 5409873 CLINICAL TRIALS ASSISTANCE 204 302890 PATIENT TYPING & SEARCH ASSISTANCE 229 90291 DONOR ASSISTANCE 579 530424 PART I, LINE 2: PATIENT ASSISTANCE GRANTS ARE AWARDED THROUGH NMDP FOUNDATION. PATIENTS APPLY FOR PRE- AND POST-TRANSPLANT SUPPORT GRANTS THROUGH AN ONLINE APPLICATION. THESE APPLICATIONS FOR PATIENT ASSISTANCE ARE TRACKED IN A ORACLE CUSTOM-BUILT MODULE AND MONITORED BY THE PATIENT OUTCOMES AND EXPERIENCES TEAM, A DEPARTMENT WITHIN NATIONAL MARROW DONOR PROGRAM (NMDP). THIS TEAM REVIEWS APPLICATIONS WEEKLY AND DETERMINES ASSISTANCE NEEDS BASED ON PUBLISHED CRITERIA, ALL WITH THE GOAL TO EQUITABLY ADMINISTER ASSISTANCE TO HELP PATIENTS OVERCOME BARRIERS BEFORE AND AFTER TRANSPLANT. SEARCH ASSISTANCE FUNDS ARE AWARDED TO COVER UNINSURED DONOR SEARCH COSTS. WHEN A TRANSPLANT CENTER (ORGANIZATIONS) RECEIVES AN INSURANCE DENIAL LETTER FOR DONOR SEARCH COSTS, THEY ARE ABLE TO COMPLETE AN APPLICATION THAT INCLUDES PROVIDING A COPY OF THE DENIAL LETTER. IF APPROVED, THE GRANT IS THEN DISTRIBUTED DIRECTLY TO THE TRANSPLANT CENTER. ALL OTHER PATIENT ASSISTANCE GRANTS ARE AWARDED TO THE APPLICANT BASED ON FINANCIAL NEED AND ARE USED TO COVER SUCH ITEMS AS UNINSURED COSTS, CO-PAYS, FOOD, LODGING, AND GROUND TRANSPORTATION. PAYMENTS ARE MADE DIRECTLY TO THE PATIENT/APPLICANT (INDIVIDUAL). DONOR ASSISTANCE REIMBURSEMENT PAYMENTS ARE PROVIDED TO APPLICANT DONORS BASED ON FINANCIAL NEED AND ARE USED TO REIMBURSE LOSS OF INCOME CAUSED BY THE DONOR TAKING UNPAID LEAVE FROM WORK IN ORDER TO DONATE LIFE-SAVING CELLS. PAYMENTS ARE MADE DIRECTLY TO THE DONOR/APPLICANT (INDIVIDUAL). X X X X 1 0 0 0 0 0 0 1 0 AMY RONNEBERG NMDP CHIEF EXECUTIVE OFFICER 0 771192 0 743820 0 23651 0 455016 0 22 0 1993701 0 172095 JOY KING CHIEF ADVANCEMENT OFFICER 123742 185614 101812 152719 4633 6949 58012 87018 9440 14161 297639 446461 21122 31682 KRISTA DUSIL CHIEF FINANCIAL OFFICER (THRU 2/24) 0 348706 0 287104 0 13945 0 27306 0 25936 0 702997 0 59562 TODD PETERSON VICE PRESIDENT, ADVANCEMENT 192154 0 91014 0 7943 0 55877 0 28162 0 375150 0 0 0 ANGIE FITZGERALD VP, CORPORATE & FOUNDATION PARTNERSH 169320 0 99485 0 5717 0 44060 0 20795 0 339377 0 0 0 ALEX MENSING SR. DIRECTOR, SUPPORTER EXPERIENCE & 138111 0 60723 0 1090 0 13198 0 33272 0 246394 0 0 0 GINA GRAVES FORMER OFFICER 0 66809 0 0 0 173149 0 0 0 3353 0 243311 0 0 KEVIN HEALY DIRECTOR, ADVANCEMENT SERVICES 127882 0 52244 0 2507 0 11621 0 31328 0 225582 0 0 0 DANIEL LEE DIRECTOR, MAJOR AND PLANNED GIFTS 143966 0 45510 0 1136 0 11781 0 20393 0 222786 0 0 0 PART I, LINE 3 METHODS USED BY RELATED ORGANIZATION, NMDP, TO ESTABLISH TOP MANAGEMENT OFFICIAL'S COMPENSATION: - COMPENSATION COMMITTEE, - INDEPENDENT COMPENSATION CONSULTANT, - COMPENSATION SURVEY OR STUDY, AND - APPROVAL BY THE COMPENSATION COMMIITTEE PLEASE ALSO SEE NARRATIVE ON SCHEDULE O, FOR FORM 990, PART VI, SECTION B, LINE 15A. PART I, LINE 4A SEVERANCE: THE FOLLOWING INDIVIDUAL RECEIVED A SEVERANCE PAYMENT DURING CALENDAR 2023: GINA GRAVES, FORMER OFFICER - $159,740 PART I, LINE 7 THE ORGANIZATION OFFERS AN ANNUAL INCENTIVE PLAN (AIP) TO ALL EMPLOYEES FOR THE CONTRIBUTIONS THEY MAKE TO THE ORGANIZATION'S RESULTS. AIP AWARDS ARE DETERMINED AS PART OF A FORMULA UTILIZING AN EMPLOYEE'S BASE PAY, THE EMPLOYEE'S AIP TARGET PERCENTAGE, AND THE ORGANIZATION'S PERFORMANCE. AIP AWARDS ARE SUBJECT TO EXECUTIVE TEAM APPROVAL AND TO ACHIEVING ESTABLISHED PERFORMANCE REQUIREMENTS. THE ORGANIZATION OFFERS A LONG-TERM INCENTIVE PLAN (LTIP) TO ELIGIBLE SENIOR LEADERSHIP EMPLOYEES. THE VARIABLE INCENTIVE COMPENSATION PLAN IS MEANT TO LINK SENIOR LEADER COMPENSATION TO ACHIEVEMENT OF LONG-TERM PERFORMANCE RESULTS AND TO ASSIST THE ORGANIZATION IN ATTRACTING AND RETAINING SENIOR LEADERS BY PROVIDING MISSION-BASED LONG-TERM INCENTIVES AND REWARDS FOR SUPERIOR PERFORMANCE. LTIP AWARDS ARE DETERMINED AS PART OF A FORMULA UTILIZING AN EMPLOYEE'S BASE SALARY IN EFFECT ON THE LAST DAY OF THE PERFORMANCE PERIOD, THE EMPLOYEE'S LTIP TARGET PERCENTAGE ESTABLISHED AT THE BEGINNING OF EACH PERFORMANCE PERIOD, AND THE OPERATING PERFORMANCE INDEX RESULTS FOR THE PERFORMANCE PERIOD. THE AWARD IS SUBJECT TO ACHIEVING ESTABLISHED PERFORMANCE REQUIREMENTS. LTIP AWARDS THAT WERE REPORTED AS AN EMPLOYEE'S DEFERRED COMPENSATION IN PRIOR YEARS AND PAID IN THE CURRENT YEAR ARE INCLUDED IN COLUMN (F). LTIP AWARDS THAT WERE PAID IN THE CURRENT YEAR ARE REPORTED IN COLUMN (B)(II). X 9 144722 FMV X AUCTION ITEMS 171 111079 FMV 0 0 1 1 PART I, COLUMN (B): THE NUMBER IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS RECEIVED. PART I, LINE 32B: THE ORGANIZATION USES A THIRD PARTY BROKERAGE TO PROCESS AND SELL CONTRIBUTIONS OF STOCK. PART III, LINE 1 AT NMDP, WE BELIEVE EACH OF US HOLDS THE KEY TO CURING BLOOD CANCERS AND DISORDERS. AS A GLOBAL NONPROFIT LEADER IN CELL THERAPY, NMDP CREATES ESSENTIAL CONNECTIONS BETWEEN RESEARCHERS AND SUPPORTERS TO INSPIRE ACTION AND ACCELERATE INNOVATION TO FIND LIFE-SAVING CURES. WITH THE HELP OF BLOOD STEM DONORS FROM THE WORLD'S MOST DIVERSE REGISTRY AND OUR EXTENSIVE NETWORK OF TRANSPLANT PARTNERS, PHYSICIANS AND CAREGIVERS, WE'RE EXPANDING ACCESS TO TREATMENT SO THAT EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. NMDP. FIND CURES. SAVE LIVES. OUR MISSION: WE SAVE LIVES THROUGH CELL THERAPY. OUR VISION: CREATE A WORLD WHERE EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. THE NMDP FOUNDATION RAISES FUNDS FOR THREE PROGRAMS CRITICAL TO OUR LIFE-SAVING MISSION: TRANSPLANT RESEARCH, PATIENT FINANCIAL ASSISTANCE AND BLOOD STEM CELL DONOR RECRUITMENT. SOME OF THE LIFE-CHANGING WORK THAT WE'RE DOING IS SOLELY FUNDED BY OUR COMMUMITY OF SUPPORTERS. WE CONDUCT RESEARCH THROUGH OUR RESEARCH PROGRAM, CIBMTR (CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH) IN COLLABORATION WITH THE MEDICAL COLLEGE OF WISCONSIN. OUR RESEARCH LEADS TO MORE LIVES SAVED AND AN ENRICHED QUALITY OF LIFE FOR THOUSANDS OF PATIENTS. THROUGH THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM AND OTHER RESEARCH GRANTS, OUTSTANDING EARLY-CAREER RESEARCHERS ARE DOING INNOVATIVE WORK TO FIND SOLUTIONS TO THE COMPLICATIONS THAT CAN ARISE AFTER TRANSPLANT. THEY'RE DEVELOPING TREATMENT APPROACHES THAT WILL HELP THE NEXT GENERATION OF TRANSPLANT PATIENTS LIVE LONGER AND HEALTHIER LIVES. PATIENT FINANCIAL ASSISTANCE HELPS COVER TRANSPLANT-RELATED COSTS NOT COVERED BY INSURANCE. THESE COSTS, INCLUDING TRANSPORTATION, LODGING, LOST WAGES AND PRESCRIPTIONS, WOULD OTHERWISE CAUSE SIGNIFICANT HARDSHIP FOR PATIENTS OR EVEN PREVENT PATIENTS FROM MOVING FORWARD WITH TRANSPLANT. NMDP CONNECTS PATIENTS WITH A MATCHING, UNRELATED DONOR - A SELFLESS STRANGER WHO CAN STEP UP AND DONATE HEALTHY BLOOD STEM CELLS TO GIVE THEM THE CHANCE AT A LIFE-SAVING TRANSPLANT. FORM 990, PART VI, SECTION A, LINE 1A THE NMDP FOUNDATION BYLAWS STATE: "THE BOARD OF DIRECTORS, BY AFFIRMATIVE VOTE OF A MAJORITY OF THE VOTING DIRECTORS, MAY DESIGNATE THREE (3) OR MORE VOTING DIRECTORS TO CONSTITUTE AN EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL HAVE THE AUTHORITY OF THE BOARD IN THE OVERSIGHT OF THE MANAGEMENT OF THE CORPORATION BETWEEN MEETINGS OF THE BOARD UNLESS OTHERWISE RESTRICTED BY RESOLUTION OF THE MAJORITY OF THE BOARD." FORM 990, PART VI, SECTION A, LINE 4 DURING FISCAL 2024, THE FOLLOWING SIGNIFICANT AMENDMENTS WERE MADE TO THE BYLAWS: - ARTICLE IV - THE CHAIR-ELECT AND IMMEDIATE PAST CHAIR ARE NOW EXCLUDED IN CALCULATING LIMITATION ON LENGTH OF SERVICE - ARTICLE VI - WAS REVISED TO MODIFY OFFICER POSITION DESCRIPTIONS AND TERMS FORM 990, PART VI, SECTION A, LINE 6 NATIONAL MARROW DONOR PROGRAM IS THE SOLE MEMBER OF THE NMDP FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A THE SOLE MEMBER, NATIONAL MARROW DONOR PROGRAM, ELECTS THE BOARD OF DIRECTORS FOR NMDP FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B THE NATIONAL MARROW DONOR PROGRAM'S BOARD OF DIRECTORS APPROVES THE ACTIONS OF NMDP FOUNDATION. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION CONTRACTED WITH AN OUTSIDE PUBLIC ACCOUNTING FIRM TO PREPARE THE FORM 990. PREPARING THE DETAILS AND SUPPORTING REPORTS FOR THE RETURN IS A COLLABORATIVE EFFORT AMONG A SMALL GROUP OF INDIVIDUALS IN THE FINANCIAL REPORTING & COMPLIANCE AREA OF FINANCE, COMPLIANCE, AND HUMAN RESOURCES. ONCE A DRAFT IS RECEIVED, IT IS REVIEWED BY THE TEAM THAT PULLED THE DETAILS TOGETHER, DIRECTOR, FINANCE AND CORPORATE CONTROLLER, NMDP FOUNDATION EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER. NMDP GENERAL COUNSEL & CHIEF COMPLIANCE OFFICER ALSO REVIEW THE GOVERNANCE SECTIONS. A COPY OF THE RETURN IS PROVIDED TO THE ORGANIZATION'S AUDIT & FINANCE COMMITTEE AND BOARD OF DIRECTORS PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY STATES THE FOLLOWING: "THE EXISTENCE OF AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST TURNS ON THE SPECIFIC FACTS AND CIRCUMSTANCES IN EACH CASE. IF A MEMBER HAS AN INTEREST WHICH MAY CONFLICT WITH THOSE OF THE ORGANIZATIONS, HE OR SHE MUST IMMEDIATELY DISCLOSE THE MATTERS AND DISCUSS THEM FULLY AND FRANKLY WITH THE APPLICABLE ORGANIZATION'S FULL BOARD OR ITS EXECUTIVE COMMITTEE, AS SET FORTH IN DETAIL BELOW. A MEMBER MUST NOT PARTICIPATE IN ANY MATTER IN WHICH THAT MEMBER MAY HAVE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST WITHOUT THE EXPRESS APPROVAL OF THE APPLICABLE ORGANIZATION'S BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS (EXECUTIVE COMMITTEE). ALL MEMBERS MUST DISCLOSE TO THE APPLICABLE ORGANIZATION'S BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE ALL CONFLICTS OF INTEREST AND REPORTABLE RELATIONSHIPS, AND MUST ANNUALLY COMPLETE AND SUBMIT THE CONFLICT OF INTEREST QUESTIONNAIRE WHICH IS REQUIRED BY THIS POLICY. WHENEVER IN THE COURSE OF EVENTS A MEMBER'S CIRCUMSTANCES CHANGE SUCH THAT THE MEMBER KNOWS OR HAS REASON TO BELIEVE THAT THE MEMBER MAY HAVE AN ACTUAL OR PERCEIVED CONFLICT OF INTEREST, SUCH MEMBER SHALL PROMPTLY DISCLOSE THE POTENTIAL CONFLICT TO THE APPLICABLE ORGANIZATION'S BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE. FOR THE PURPOSES OF THIS ARTICLE, A MEMBER MAY FORMALLY DISCLOSE A CONFLICT OR REPORTABLE RELATIONSHIP TO THE NMDP CHIEF EXECUTIVE OFFICER (CEO), THE CHIEF ADVANCEMENT OFFICER, OR THE NMDP LEGAL TEAM, AS APPLICABLE, WHO SHALL INFORM THE APPLICABLE ORGANIZATION'S BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE FOR RESOLUTION. AS NOTED HEREIN, IF THE POTENTIAL CONFLICT INVOLVES A DIRECTOR OR COMMITTEE MEMBER, THAT DIRECTOR OR COMMITTEE MEMBER SHALL NOT PARTICIPATE IN OR VOTE UPON SUCH MATTERS UNTIL THE QUESTION OF THE EXISTENCE OF THE CONFLICT OF INTEREST HAS BEEN RESOLVED IN ACCORDANCE WITH THIS POLICY. LIKEWISE, AN OFFICER OR KEY EMPLOYEE MAY NOT BECOME SUBSTANTIALLY INVOLVED IN DECISION-MAKING INVOLVING ANY COVERED LITIGATION, CONTRACT OR TRANSACTION UNTIL THE RESOLUTION OF THE MATTER IN ACCORDANCE WITH THIS POLICY." FORM 990, PART VI, SECTION B, LINE 15 THE CHIEF ADVANCEMENT OFFICER REPORTS DIRECTLY TO THE NMDP CHIEF EXECUTIVE OFFICER (CEO) AND IS CONSIDERED A KEY EMPLOYEE PER IRS DEFINITION. THE COMPENSATION OF THE CHIEF ADVANCEMENT OFFICER IS REVIEWED, EVALUATED, AND SET IN ACCORDANCE WITH THE NMDP BYLAWS AND COMPENSATION COMMITTEE CHARTER. THE NMDP BYLAWS STATE: "THE COMPENSATION COMMITTEE SHALL BE COMPRISED ONLY OF VOTING DIRECTORS AND SHALL INCLUDE THE CHAIR OF THE BOARD AND AT LEAST ONE (1) NONOFFICER BOARD MEMBER AS VOTING COMMITTEE MEMBERS. THE COMPENSATION COMMITTEE SHALL REVIEW AND EVALUATE THE OVERALL COMPENSATION AND BENEFIT STRUCTURE OF THE CORPORATION AND SHALL HAVE SUCH OTHER AUTHORITY AND RESPONSIBILITIES AS SET FORTH IN THE COMPENSATION COMMITTEE CHARTER." THE COMPENSATION COMMITTEE CHARTER STATES: "THE COMMITTEE SHALL REVIEW AND EVALUATE THE OVERALL COMPENSATION AND BENEFIT STRUCTURE OF THE CORPORATION AND APPROVE AND ADOPT A COMPENSATION PHILOSOPHY AND PRINCIPLES CONSISTENT WITH THE CORPORATION'S NON-FOR-PROFIT STATUS (THE "COMPENSATION PHILOSOPHY AND PRINCIPLES"). THE COMMITTEE SHALL CONDUCT THE CHIEF EXECUTIVE OFFICER ("CEO") PERFORMANCE EVALUATION. THE COMMITTEE SHALL MAKE CEO TOTAL COMPENSATION AND BENEFIT RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE, CONSISTENT WITH THE COMPENSATION PHILOSOPHY AND PRINCIPLES. IN MAKING COMPENSATION AND BENEFIT RECOMMENDATIONS FOR THE CEO, THE COMMITTEE SHALL UTILIZE, AMONG OTHER THINGS, COMPARABILITY DATA FOR COMPLIANCE WITH IRS INTERMEDIATE SANCTION PROVISIONS SO AS TO ALLOW THE CORPORATION TO TAKE ADVANTAGE OF THE REBUTTABLE PRESUMPTION OF REASONABLENESS. ON A PERIODIC BASIS, THE COMMITTEE SHALL OBTAIN COMPARABILITY DATA FROM AND INDEPENDENT COMPENSATION CONSULTANT. IN ADDITION, THE COMMITTEE SHALL ADVISE THE CEO IN HIS/HER EVALUATION OF AND DECISIONS REGARDING THE COMPENSATION OF AND BENEFITS FOR SENIOR CORPORATION EMPLOYEES, AS WELL AS THE PRESIDENT (OR EQUIVALENT LEADER) OF ANY SUBSIDIARY OF THE CORPORATION REPORTING TO THE CEO (TOGETHER, "SENIOR LEADERSHIP"). IN ADVISING THE CEO IN MAKING HIS/HER COMPENSATION AND BENEFIT DECISIONS FOR SENIOR LEADERSHIP, THE COMMITTEE SHALL ENSURE THAT SUCH DECISIONS ARE CONSISTENT WITH THE COMPENSATION PHILOSOPHY AND PRINCIPLES, AND UTILIZE, AMONG OTHER THINGS, COMPARABILITY DATA FOR COMPLIANCE WITH IRS INTERMEDIATE SANCTION PROVISIONS. IF DECISIONS PROPOSED BY THE CEO ARE OUTSIDE THE PARAMETERS OF THE COMPENSATION PHILOSOPHY AND PRINCIPLES, THE CEO MUST OBTAIN THE COMMITTEE'S APPROVAL PRIOR TO IMPLEMENTATION." FORM 990, PART VI, SECTION C, LINE 19 THE CONFLICT OF INTEREST POLICY, ARTICLES OF INCORPORATION AND CONSOLIDATED AUDITED FINANCIAL STATEMENTS AND ADDITIONAL CONSOLIDATING INFORMATION ARE ALL MADE AVAILABLE TO THE PUBLIC UPON REQUEST. THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON OUR WEBSITE. SUMMARY FINANCIAL STATEMENTS ARE ALSO INCLUDED IN OUR ANNUAL REPORT, WHICH IS MAILED TO KEY STAKEHOLDERS AND POSTED ON OUR WEBSITE. ADDITIONALLY, ARTICLES OF INCORPORATION ARE AVAILABLE AT THE MN OFFICE OF THE SECRETARY OF STATE, AND CONSOLIDATED AUDITED FINANCIAL STATEMENTS MAY BE OBTAINED AT THE MN OFFICE OF THE ATTORNEY GENERAL. NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 554011206 840865803 TRANSPLANTS CO 501(C)(3) LINE 10 N/A 0 NMDP MEXICO VERACRUZ AV 93 101 PISO CUIDAD DE MEXICO CONDESA MX 06140 RECRUITMENT MX NMDP 0 NMDP COLLECTION SERVICES LLC 500 N 5TH ST MINNEAPOLIS MN 554011206 811248190 CELLULAR THERAPY MN N/A C 0 CLEAR INSURANCE LTD 62 FORUM LN 3RD FL PO BOX 30600 GRAND CAYMAN CJ KY1-1203 840865803 CAPTIVE INSURANCE CJ N/A C 0 NMDP AUXILIARY SERVICES LLC 500 N 5TH STREET MINNEAPOLIS MN 554011206 811248190 CELL THERAPY MN N/A C 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 NATIONAL MARROW DONOR PROGRAM B 5143966 COST NATIONAL MARROW DONOR PROGRAM C 7586216 COST NATIONAL MARROW DONOR PROGRAM P 1493184 COST